Investegate |C4X Discovery Announcements | C4X Discovery: Full Year Results
Investegate announcements from C4X Discovery, Full Year Results
Stay updated with breaking news from Morphic Therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from C4X Discovery, Full Year Results
Co-founders anda key investor now rank amongst Forbes' 400 richest Americans thanks to pandemic, are worth billions due to soaring stock prices
Operator Thank you for standing by. Welcome to Schrodinger's conference call to review the company's first quarter financial results. My name is Kevin, and I'll be your operator for today's call. [Operator Instructions] Now, I would like to introduce your host for today's conference call, Jaren Madden, Senior Vice President of Investor Relations and Corporate Communications. Please go ahead. Jaren Madden -- Senior Vice President, Investor Relations and Corporate Communications Thank you, and hello, everyone. Welcome to today's call during which we will provide an update on the company and re...
Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term April 28, 2021 16:01 ET | Source: Morphic Therapeutic Morphic Therapeutic Waltham, Massachusetts, UNITED STATES WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to its Board of Directors. Ms. Gray is an accomplished l...
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering March 02, 2021 20:25 ET | Source: Morphic Therapeutic Morphic Therapeutic Waltham, Massachusetts, UNITED STATES WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $70...